Skip to main content
. 2023 Aug 28;14(9):1708. doi: 10.3390/genes14091708

Figure 1.

Figure 1

Overall (A,C) and progression-free (B,D) survival results of the study participants. Grouping was performed based on the PAM50 subtypes (A,B) and PAM50 risk of recurrence (ROR) scores (C,D). Significant differences between the survival times of any patient groups were observed only in the case of PFS.